Share-based Payment Arrangement, Expense of KALA BIO, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
KALA BIO, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • KALA BIO, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $2,044,000, a 0.39% increase year-over-year.
  • KALA BIO, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,688,000, a 0.22% increase year-over-year.
  • KALA BIO, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $8,389,000, a 12% increase from 2023.
  • KALA BIO, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,463,000, a 6.5% increase from 2022.
  • KALA BIO, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7,008,000, a 56% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

KALA BIO, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,688,000 $2,044,000 +$8,000 +0.39% 01 Jul 2025 30 Sep 2025 10-Q 19 Nov 2025 2025 Q3
Q2 2025 $8,680,000 $2,240,000 +$357,000 +19% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $8,323,000 $2,310,000 -$66,000 -2.8% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $8,389,000 $2,094,000 -$280,000 -12% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 $8,669,000 $2,036,000 -$367,000 -15% 01 Jul 2024 30 Sep 2024 10-Q 19 Nov 2025 2025 Q3
Q2 2024 $9,036,000 $1,883,000 +$521,000 +38% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $8,515,000 $2,376,000 +$1,052,000 +79% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2025 2025 Q1
Q4 2023 $7,463,000 $2,374,000 +$1,414,000 +147% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 $6,049,000 $2,403,000 +$1,076,000 +81% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $4,973,000 $1,362,000 -$554,000 -29% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $5,527,000 $1,324,000 -$1,481,000 -53% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $7,008,000 $960,000 -$1,788,000 -65% 01 Oct 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
Q3 2022 $8,796,000 $1,327,000 -$2,601,000 -66% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $11,397,000 $1,916,000 -$2,794,000 -59% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $14,191,000 $2,805,000 -$1,897,000 -40% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $16,088,000 $2,748,000 -$1,313,000 -32% 01 Oct 2021 31 Dec 2021 10-K 03 Mar 2023 2022 FY
Q3 2021 $17,401,000 $3,928,000 -$333,000 -7.8% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $17,734,000 $4,710,000 +$2,217,000 +89% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $15,517,000 $4,702,000 +$2,205,000 +88% 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q4 2020 $13,312,000 $4,061,000 +$1,736,000 +75% 01 Oct 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
Q3 2020 $11,576,000 $4,261,000 +$1,689,000 +66% 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $9,887,000 $2,493,000 -$128,000 -4.9% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $10,015,000 $2,497,000 +$24,000 +0.97% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $9,991,000 $2,325,000 +$127,000 +5.8% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $9,864,000 $2,572,000 +$307,000 +14% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $9,557,000 $2,621,000 +$330,000 +14% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $9,227,000 $2,473,000 +$612,000 +33% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $8,615,000 $2,198,000 +$697,000 +46% 01 Oct 2018 31 Dec 2018 10-K 12 Feb 2020 2019 FY
Q3 2018 $7,918,000 $2,265,000 +$1,284,000 +131% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019 2019 Q3
Q2 2018 $6,634,000 $2,291,000 +$1,724,000 +304% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $4,910,000 $1,861,000 +$1,339,000 +257% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 $3,571,000 $1,501,000 01 Oct 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
Q3 2017 $981,000 +$427,000 +77% 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $567,000 -$301,000 -35% 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $522,000 01 Jan 2017 31 Mar 2017 10-Q 10 May 2018 2018 Q1
Q3 2016 $554,000 01 Jul 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $868,000 01 Apr 2016 30 Jun 2016 10-Q 31 Aug 2017 2017 Q2

KALA BIO, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $8,389,000 +$926,000 +12% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 $7,463,000 +$455,000 +6.5% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 $7,008,000 -$9,080,000 -56% 01 Jan 2022 31 Dec 2022 10-K 29 Mar 2024 2023 FY
2021 $16,088,000 +$2,776,000 +21% 01 Jan 2021 31 Dec 2021 10-K 03 Mar 2023 2022 FY
2020 $13,312,000 +$3,321,000 +33% 01 Jan 2020 31 Dec 2020 10-K 29 Mar 2022 2021 FY
2019 $9,991,000 +$1,376,000 +16% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2021 2020 FY
2018 $8,615,000 +$5,044,000 +141% 01 Jan 2018 31 Dec 2018 10-K 12 Feb 2020 2019 FY
2017 $3,571,000 +$1,502,000 +73% 01 Jan 2017 31 Dec 2017 10-K 12 Mar 2019 2018 FY
2016 $2,069,000 01 Jan 2016 31 Dec 2016 10-K 02 Apr 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.